XXII Market Analysis
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 0.07
- P/S (TTM)
- 0.23
- EV/EBITDA
- -0.47
Profitability & growth
- ROE (TTM)
- -103.6%
- Operating margin
- -235.8%
- Revenue growth YoY
- -43.3%
- Dividend yield
- —
- Beta
- 0.67
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About 22nd Century Group Inc
Company profile22nd Century Group Inc (Ticker: XXII) is an innovative biopharmaceutical and agricultural leader dedicated to tobacco harm reduction through advanced genetic engineering. The company specializes in the development of low-nicotine tobacco products aimed at reducing nicotine addiction and enhancing public health. Additionally, 22nd Century is strategically diversifying into the burgeoning hemp and cannabis markets, aligning itself with the rapid growth of the legal cannabis sector. By prioritizing scientific research and regulatory compliance, 22nd Century presents a compelling investment…
Classification
- Sector
- Consumer Defensive
- Industry
- Tobacco
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 321 FARMINGTON ROAD, MOCKSVILLE, NC
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
